Immunogenic peptides specific to bcma and taci antigens for treatment of cancer

Abstract

This disclosure relates to immunogenic peptides that are specific to B-cell maturation antigen (BCMA) and Transmembrane activator and CAML interactor (TACI), and methods of use thereof.

1 . A peptide comprising:
 (a) an amino acid sequence that is identical to the amino acid sequence set forth in any one of SEQ ID NO: 13-17, or differs by 1 to 4 amino acid residues, wherein the amino acid at position 1 of SEQ ID NOs: 13-17 is unaltered; or   (b) a first amino acid sequence consisting of an amino acid sequence that is at least 60% identical to any one of SEQ ID NOs: 1-17; and a second amino acid sequence that is heterologous to the first amino acid sequence;   wherein the peptide (i) binds to a major histocompatibility complex (MHC) molecule, or (ii) in association with a MHC molecule, is recognized by an antigen specific T cell receptor on a T cell.   
     
     
         2 .- 20 . (canceled) 
     
     
         21 . A nucleic acid encoding the peptide of  claim 1 . 
     
     
         22 . A vector comprising a nucleic acid encoding the peptide of  claim 1 . 
     
     
         23 . (canceled) 
     
     
         24 . A cultured cell comprising the vector of  claim 22 , wherein the nucleic acid is operably linked to a promoter, a regulatory element, or an expression control sequence. 
     
     
         25 .- 27 . (canceled) 
     
     
         28 . A virus comprising a nucleic acid encoding the peptide of  claim 1 . 
     
     
         29 . (canceled) 
     
     
         30 . A combination of at least two different peptides, wherein the at least two different peptides are (i) selected from the group consisting of peptides having an amino acid sequence set forth in SEQ ID NOs: 13-17; or (ii) selected from the group consisting of peptides having an amino acid sequence that is at least 60% identical to any one of SEQ ID NOs: 13-17, wherein the at least two different peptides (i) bind to a major histocompatibility complex (MHC) molecule, or (ii) in association with a MHC molecule, is recognized by an antigen specific T cell receptor on a T cell. 
     
     
         31 . (canceled) 
     
     
         32 . A pharmaceutical composition comprising
 the combination of  claim 30 ; and   a pharmaceutically acceptable carrier.   
     
     
         33 . (canceled) 
     
     
         34 . (canceled) 
     
     
         35 . A composition comprising an isolated dendritic cell, wherein the isolated dendritic cell presents a peptide on its surface, wherein the peptide comprises at least one major histocompatibility complex (MHC) class I peptide epitope of one or both of BCMA antigen (SEQ ID NO: 18) and TACI antigen (SEQ ID NO: 19). 
     
     
         36 .- 89 . (canceled) 
     
     
         90 . A method of identifying a T cell antigen receptor sequence for TACI, the method comprising
 (a) generating and/or proliferating TACI-specific cytotoxic T cells by contacting one or more cytotoxic T cells with one or more antigen presenting cells pulsed with a peptide comprising the amino acid sequence of any one of SEQ ID NOs: 15-17 and   (b) determining the T cell antigen receptor sequence for TACI in the TACI-specific cytotoxic T cells.   
     
     
         91 . (canceled) 
     
     
         92 . A composition comprising:
 a nanoparticle, and a peptide comprising an amino acid sequence that is at least 60% identical to any one of SEQ ID NOs: 1-17, wherein the peptide (i) binds to a major histocompatibility complex (MHC) molecule, or (ii) in association with a MHC molecule, is recognized by an antigen specific T cell receptor on a T cell.   
     
     
         93 .- 105 . (canceled) 
     
     
         106 . A method for treating a human subject having a cancer, comprising: administering to the human subject the composition of  claim 92 . 
     
     
         107 .- 112 . (canceled)